These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 35875124)
21. Molecular Characteristics of m6A Regulators and Tumor Microenvironment Infiltration in Soft Tissue Sarcoma: A Gene-Based Study. Xiao KW; Yang ZQ; Yan X; Liu ZB; Yang M; Guo LY; Cai L Front Bioeng Biotechnol; 2022; 10():846812. PubMed ID: 35519620 [No Abstract] [Full Text] [Related]
22. m6A Regulators Mediated Methylation Modification Patterns and Tumor Microenvironment Infiltration Characterization In Nasopharyngeal Carcinoma. Liu Z; He J; Han J; Yang J; Liao W; Chen N Front Immunol; 2021; 12():762243. PubMed ID: 35069534 [TBL] [Abstract][Full Text] [Related]
23. Characterization of m6A Methylation Modification Patterns in Colorectal Cancer Determines Prognosis and Tumor Microenvironment Infiltration. Yue Q; Zhang Y; Wang F; Cao F; Bai J; Duan X J Immunol Res; 2022; 2022():8766735. PubMed ID: 35692505 [TBL] [Abstract][Full Text] [Related]
24. Construction of a risk prediction model using m6A RNA methylation regulators in prostate cancer: comprehensive bioinformatic analysis and histological validation. Quan Y; Zhang X; Ping H Cancer Cell Int; 2022 Jan; 22(1):33. PubMed ID: 35045837 [TBL] [Abstract][Full Text] [Related]
25. m6A Regulator-Associated Modification Patterns and Immune Infiltration of the Tumor Microenvironment in Hepatocarcinoma. Li J; Wang W; Zhou Y; Liu L; Zhang G; Guan K; Cui X; Liu X; Huang M; Cui G; Sun R Front Cell Dev Biol; 2021; 9():687756. PubMed ID: 34277630 [No Abstract] [Full Text] [Related]
26. Analysis of N6-Methyladenosine Modification Patterns and Tumor Immune Microenvironment in Pancreatic Adenocarcinoma. Liu Y; Li G; Yang Y; Lu Z; Wang T; Wang X; Liu J Front Genet; 2021; 12():752025. PubMed ID: 35046996 [No Abstract] [Full Text] [Related]
27. A signature based on m6A pattern and tumor microenvironment infiltration in clear cell renal cell carcinoma. Yang C; Yu T; Li Q; Xie F; Lin Q Am J Transl Res; 2022; 14(7):4931-4947. PubMed ID: 35958449 [TBL] [Abstract][Full Text] [Related]
28. N Li C; Zhu M; Gao C; Lu F; Chen H; Liu J; Zhong W Front Biosci (Landmark Ed); 2024 Jan; 29(1):33. PubMed ID: 38287827 [TBL] [Abstract][Full Text] [Related]
29. m6A Modification Patterns With Distinct Immunity, Metabolism, and Stemness Characteristics in Soft Tissue Sarcoma. Huang ZD; Lin LL; Liu ZZ; Hu C; Gu HY; Wei RX Front Immunol; 2021; 12():765723. PubMed ID: 35003079 [TBL] [Abstract][Full Text] [Related]
30. m6A Methylation Patterns and Tumor Microenvironment Infiltration Characterization in Clear-Cell Renal Cell Carcinoma. Ma T; Wang J; Liu X; Zhang W; Meng L; Zhang Y Front Genet; 2022; 13():864549. PubMed ID: 35528542 [TBL] [Abstract][Full Text] [Related]
31. Integrating m6A Regulators-Mediated Methylation Modification Models and Tumor Immune Microenvironment Characterization in Caucasian and Chinese Low-Grade Gliomas. Liu W; Li C; Wu Y; Xu W; Chen S; Zhang H; Huang H; Zhao S; Wang J Front Cell Dev Biol; 2021; 9():725764. PubMed ID: 34900988 [No Abstract] [Full Text] [Related]
32. Correlation analysis of m6A-modified regulators with immune microenvironment infiltrating cells in lung adenocarcinoma. Ye W; Huang T PLoS One; 2022; 17(2):e0264384. PubMed ID: 35196365 [TBL] [Abstract][Full Text] [Related]
33. Use of Novel m6A Regulator-mediated Methylation Modification Patterns in Distinct Tumor Microenvironment Profiles to Identify and Predict Glioma Prognosis and Progression, T-cell Dysfunction, and Clinical Response to ICI Immunotherapy. Zhao B; Xiang Z; Wu B; Zhang X; Feng N; Wei Y; Zhang W Curr Pharm Des; 2023; 29(1):60-78. PubMed ID: 36503445 [TBL] [Abstract][Full Text] [Related]
34. Identification of an N6-methyladenosine (m6A)-related signature associated with clinical prognosis, immune response, and chemotherapy in primary glioblastomas. Cai Z; Zhang J; Liu Z; Su J; Xu J; Li Z; Meng H; Zhang H; Huang M; Zhao D; Duan C; He X Ann Transl Med; 2021 Aug; 9(15):1241. PubMed ID: 34532378 [TBL] [Abstract][Full Text] [Related]
35. M6A regulator-mediated immune infiltration and methylation modification in hepatocellular carcinoma microenvironment and immunotherapy. Zhao K; Wei B; Zhang Y; Shi W; Zhang G; Wang Z Front Pharmacol; 2022; 13():1052177. PubMed ID: 36438800 [No Abstract] [Full Text] [Related]
36. Identification of m6A modification patterns and development of m6A-hypoxia prognostic signature to characterize tumor microenvironment in triple-negative breast cancer. Shen X; Zhong J; He J; Han J; Chen N Front Immunol; 2022; 13():978092. PubMed ID: 36105819 [TBL] [Abstract][Full Text] [Related]
37. m Sun M; Xie M; Zhang T; Wang Y; Huang W; Xia L Front Immunol; 2021; 12():739768. PubMed ID: 34616403 [TBL] [Abstract][Full Text] [Related]
38. Novel RNA N6-methyladenosine regulator related signature for predicting clinical and immunological characteristics in breast cancer. Zhang J; Liu G; Dai Z; Xie F; Zheng R; Yuan B; Guo L Gene; 2023 Feb; 853():147095. PubMed ID: 36464173 [TBL] [Abstract][Full Text] [Related]
39. N6-methyladenosine Regulator-Mediated Immune Genes Identify Breast Cancer Immune Subtypes and Predict Immunotherapy Efficacy. Zhang MM; Lin YL; Zeng WF; Li Y; Yang Y; Liu M; Ye YJ; Jiang KW; Wang S; Wang S Front Genet; 2021; 12():790888. PubMed ID: 34976022 [TBL] [Abstract][Full Text] [Related]
40. Characterization of m6A methylation modifications in gastric cancer. Yin W; Huo Z; Zuo J; Wang H; Chen B; Zhou L Aging (Albany NY); 2024 Jan; 16(1):89-105. PubMed ID: 38206646 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]